<?xml version='1.0' encoding='utf-8'?>
<document id="18479178"><sentence text="Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study."><entity charOffset="33-45" id="DDI-PubMed.18479178.s1.e0" text="rivastigmine" /><entity charOffset="137-146" id="DDI-PubMed.18479178.s1.e1" text="memantine" /><pair ddi="false" e1="DDI-PubMed.18479178.s1.e0" e2="DDI-PubMed.18479178.s1.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s1.e0" e2="DDI-PubMed.18479178.s1.e1" /></sentence><sentence text="It has been shown that combining memantine and a cholinesterase inhibitor, which each affect different neurotransmitter systems, may offer further improvements in efficacy over either treatment alone in patients with Alzheimer's disease"><entity charOffset="33-42" id="DDI-PubMed.18479178.s2.e0" text="memantine" /></sentence><sentence text=" The present study was conducted to determine if memantine has any effects on the steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease"><entity charOffset="49-58" id="DDI-PubMed.18479178.s3.e0" text="memantine" /><entity charOffset="115-127" id="DDI-PubMed.18479178.s3.e1" text="rivastigmine" /><pair ddi="false" e1="DDI-PubMed.18479178.s3.e0" e2="DDI-PubMed.18479178.s3.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s3.e0" e2="DDI-PubMed.18479178.s3.e1" /></sentence><sentence text="" /><sentence text="Rivastigmine-treated Alzheimer's disease patients who had been maintained on a fixed regimen of twice-daily rivastigmine for &gt;or=2 months were eligible to enter the study"><entity charOffset="0-12" id="DDI-PubMed.18479178.s5.e0" text="Rivastigmine" /><entity charOffset="108-120" id="DDI-PubMed.18479178.s5.e1" text="rivastigmine" /><pair ddi="false" e1="DDI-PubMed.18479178.s5.e0" e2="DDI-PubMed.18479178.s5.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s5.e0" e2="DDI-PubMed.18479178.s5.e1" /></sentence><sentence text=" Sixteen patients (seven males and nine females, age range 64-88 years, weight range 51" /><sentence text="8-104 kg) were enrolled in this open-label, crossover study, which consisted of a 28-day screening period, a 36-hour baseline period, and a 35-day combination treatment phase" /><sentence text=" The patients spent the baseline period and day 35 at the study centre, where plasma samples for pharmacokinetic evaluation were taken at specified time intervals over a 10-hour time period" /><sentence text=" In addition, 10-hour (evening pre-dose) memantine plasma samples were taken on days 21, 34 and 35"><entity charOffset="41-50" id="DDI-PubMed.18479178.s9.e0" text="memantine" /></sentence><sentence text="" /><sentence text="The combination of memantine (10 mg twice daily) with rivastigmine (1"><entity charOffset="19-28" id="DDI-PubMed.18479178.s11.e0" text="memantine" /><entity charOffset="54-66" id="DDI-PubMed.18479178.s11.e1" text="rivastigmine" /><pair ddi="false" e1="DDI-PubMed.18479178.s11.e0" e2="DDI-PubMed.18479178.s11.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s11.e0" e2="DDI-PubMed.18479178.s11.e1" /></sentence><sentence text="5-6 mg twice daily) was safe and well tolerated" /><sentence text=" At each dose level of rivastigmine, the area under the concentration-time curve (AUC) values of rivastigmine and its metabolite as well as the metabolite-to-parent AUC ratios were unaffected by co-administration of memantine, confirming the absence of a meaningful pharmacokinetic drug-drug interaction"><entity charOffset="23-35" id="DDI-PubMed.18479178.s13.e0" text="rivastigmine" /><entity charOffset="97-109" id="DDI-PubMed.18479178.s13.e1" text="rivastigmine" /><entity charOffset="216-225" id="DDI-PubMed.18479178.s13.e2" text="memantine" /><pair ddi="false" e1="DDI-PubMed.18479178.s13.e0" e2="DDI-PubMed.18479178.s13.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s13.e0" e2="DDI-PubMed.18479178.s13.e1" /><pair ddi="false" e1="DDI-PubMed.18479178.s13.e0" e2="DDI-PubMed.18479178.s13.e2" /><pair ddi="false" e1="DDI-PubMed.18479178.s13.e1" e2="DDI-PubMed.18479178.s13.e1" /><pair ddi="false" e1="DDI-PubMed.18479178.s13.e1" e2="DDI-PubMed.18479178.s13.e2" /></sentence><sentence text="" /><sentence text="Under the study conditions, the extent of systemic exposure to rivastigmine and its metabolite NAP226-90 at steady state did not appear to be affected by concomitant administration of memantine"><entity charOffset="63-75" id="DDI-PubMed.18479178.s15.e0" text="rivastigmine" /><entity charOffset="184-193" id="DDI-PubMed.18479178.s15.e1" text="memantine" /><pair ddi="false" e1="DDI-PubMed.18479178.s15.e0" e2="DDI-PubMed.18479178.s15.e0" /><pair ddi="false" e1="DDI-PubMed.18479178.s15.e0" e2="DDI-PubMed.18479178.s15.e1" /></sentence><sentence text="" /></document>